{"organizations": [], "uuid": "6962f8ff95dce590d0e22e7caef1287b5e83bf8e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-inspiremd-announces-commercial-launch-and-first-sales-of-cguarda-eps-in-india.html", "country": "US", "domain_rank": 767, "title": "InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.316, "site_type": "news", "published": "2018-02-20T17:00:00.000+02:00", "replies_count": 0, "uuid": "6962f8ff95dce590d0e22e7caef1287b5e83bf8e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-inspiremd-announces-commercial-launch-and-first-sales-of-cguarda-eps-in-india.html", "ord_in_thread": 0, "title": "InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India", "locations": [], "entities": {"persons": [{"name": "agustin gago", "sentiment": "none"}], "locations": [{"name": "india tel aviv", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}, {"name": "india", "sentiment": "none"}], "organizations": [{"name": "inc.", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "central drugs standard control organisation", "sentiment": "none"}, {"name": "hester diagnostics pvt. ltd.", "sentiment": "none"}, {"name": "ministry of health & family welfare", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TEL AVIV, ISRAEL, Feb. 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the commercial launch and first sales of its CGuard™ Embolic Prevention System (EPS) in India. As previously announced, CGuard™ EPS was recently granted marketing clearance by India’s Central Drugs Standard Control Organisation within the Ministry of Health & Family Welfare. The Company also recently announced it had signed Hester Diagnostics Pvt. Ltd. as its exclusive distributor in India.\n“We are pleased with our launch of CGuard™ EPS in India, immediately following receipt of regulatory marketing clearance. This illustrates our ability to enter new markets and it further validates our capabilities to develop and support a global footprint and distribution model,” said Agustin Gago, EVP and Chief Commercial Officer of InspireMD. “We believe India represents an attractive and growing market for CGuard™ EPS, and constitutes another milestone in our expansion strategy across Asia.”\nAbout InspireMD, Inc.\nInspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.\nInspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is Quote: d on the NYSE American under the ticker symbol NSPR and certain warrants are Quote: d on the NYSE American under the ticker symbol NSPR.WS.\nForward-looking Statements\nThis press release contains \"forward-looking statements.\" Such statements may be preceded by the words \"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\" \"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\nInvestor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: craigs@inspiremd.com Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: NSPR@crescendo-ir.com\nSource:InspireMD, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=NpoKkm2JUStCyJfAGnzE8IxB1a3KZCJXmY-Vo-Utff_Zt1aCgy9tE8wOlilMjYOh5C3KF3HjQB41TrO1Vgy6Ag==", "https://www.globenewswire.com/Tracker?data=GEeMy4xqmDJfd9wLLiPFBuC0Jyx0-6jKigqaePjIMcGxcbDOEbGwgbRx7czYuHOLRb__PWE_YCmyFvzrCNdVIw==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/bd26f8ab-01c6-447f-a581-6d2e5d706f08"], "published": "2018-02-20T17:00:00.000+02:00", "crawled": "2018-02-20T20:17:48.008+02:00", "highlightTitle": ""}